We Offer Worldwide Shipping
Login Wishlist

Angeloylgomisin O

$672

  • Brand : BIOFRON

  • Catalogue Number : BD-P0111

  • Specification : 97.0%(HPLC)

  • CAS number : 83864-69-1

  • Formula : C28H34O8

  • Molecular Weight : 498.56

  • PUBCHEM ID : 91864462

  • Volume : 25mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0111

Analysis Method

HPLC,NMR,MS

Specification

97.0%(HPLC)

Storage

2-8°C

Molecular Weight

498.56

Appearance

Powder

Botanical Source

Structure Type

Lignans

Category

SMILES

CC=C(C)C(=O)OC1C(C(CC2=CC3=C(C(=C2C4=C(C(=C(C=C14)OC)OC)OC)OC)OCO3)C)C

Synonyms

IUPAC Name

[(8R,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] (Z)-2-methylbut-2-enoate

Applications

Density

1.2±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

257.4±31.5 °C

Boiling Point

608.3±55.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C28H34O8/c1-9-14(2)28(29)36-23-16(4)15(3)10-17-11-20-25(35-13-34-20)26(32-7)21(17)22-18(23)12-19(30-5)24(31-6)27(22)33-8/h9,11-12,15-16,23H,10,13H2,1-8H3/b14-9-/t15-,16-,23+/m0/s1

InChl Key

PLKFSXFJGNZAER-XXDSNBTQSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:83864-69-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

25313075

Abstract

Virioplankton play a crucial role in aquatic ecosystems as top-down regulators of bacterial populations and agents of horizontal gene transfer and nutrient cycling. However, the biology and ecology of virioplankton populations in the environment remain poorly understood. Ribonucleotide reductases (RNRs) are ancient enzymes that reduce ribonucleotides to deoxyribonucleotides and thus prime DNA synthesis. Composed of three classes according to O2 reactivity, RNRs can be predictive of the physiological conditions surrounding DNA synthesis. RNRs are universal among cellular life, common within viral genomes and virioplankton shotgun metagenomes (viromes), and estimated to occur within >90% of the dsDNA virioplankton sampled in this study. RNRs occur across diverse viral groups, including all three morphological families of tailed phages, making these genes attractive for studies of viral diversity. Differing patterns in virioplankton diversity were clear from RNRs sampled across a broad oceanic transect. The most abundant RNRs belonged to novel lineages of podoviruses infecting α-proteobacteria, a bacterial class critical to oceanic carbon cycling. RNR class was predictive of phage morphology among cyanophages and RNR distribution frequencies among cyanophages were largely consistent with the predictions of the “kill the winner-cost of resistance” model. RNRs were also identified for the first time to our knowledge within ssDNA viromes. These data indicate that RNR polymorphism provides a means of connecting the biological and ecological features of virioplankton populations.

KEYWORDS

viral ecology, viral evolution, phage replication

Title

Ribonucleotide reductases reveal novel viral diversity and predict biological and ecological features of unknown marine viruses

Author

Eric G. Sakowski,a Erik V. Munsell,b Mara Hyatt,a William Kress,c Shannon J. Williamson,d Daniel J. Nasko,e Shawn W. Polson,a,e,f,g and K. Eric Wommacka,g,h,1

Publish date

2014 Nov 4

PMID

31940319

Abstract

Objective
To estimate healthcare expenditures that could be impacted by advanced diagnostic testing for patients hospitalized with meningitis or encephalitis

Methods
Patients hospitalized with meningitis (N = 23,933) or encephalitis (N = 7,858) in the U.S. were identified in the 2010-2014 Truven Health MarketScan Commercial Claims and Encounters Database using ICD-9-CM diagnostic codes. The database included an average of 40.8 million commercially insured enrollees under age 65 per year. Clinical, demographic and healthcare utilization criteria were used to identify patient subgroups early in their episode who were at risk to have high inpatient expenditures. Healthcare expenditures of patients within each subgroup were bifurcated: those expenditures that remained five days after the patient could be classified into the subgroup versus those that had occurred previously.

Results
The hospitalization episode rate per 100,000 enrollee-years for meningitis was 13.0 (95% CI: 12.9-13.2) and for encephalitis was 4.3 (95% CI: 4.2-4.4), with mean inpatient expenditures of $36,891 (SD = $92,636) and $60,181 (SD = $130,276), respectively. If advanced diagnostic testing had been administered on the day that a patient could be classified into a subgroup, then a test with a five-day turnaround time could impact the following mean inpatient expenditures that remained by subgroup for patients with meningitis or encephalitis, respectively: had a neurosurgical procedure ($83,337 and $56,020), had an ICU stay ($34,221 and $46,051), had HIV-1 infection or a previous organ transplant ($37,702 and $62,222), were age <1 year ($35,371 and $52,812), or had a hospital length of stay >2 days ($18,325 and $30,244).

Discussion
Inpatient expenditures for patients hospitalized with meningitis or encephalitis were substantial and varied widely. Patient subgroups who had high healthcare expenditures could be identified early in their stay, raising the potential for advanced diagnostic testing to lower these expenditures.

Title

Exploratory analysis of the potential for advanced diagnostic testing to reduce healthcare expenditures of patients hospitalized with meningitis or encephalitis

Author

Brent D. Fulton, Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Resources, Supervision, Writing - original draft, Writing - review & editing,1,* David G. Proudman, Conceptualization, Formal analysis, Methodology, Validation, Writing - original draft, Writing - review & editing,1 Hannah A. Sample, Formal analysis, Resources, Writing - review & editing,2 Jeffrey M. Gelfand, Formal analysis, Writing - review & editing,3 Charles Y. Chiu, Conceptualization, Funding acquisition, Writing - review & editing,4,5,6 Joseph L. DeRisi, Conceptualization, Funding acquisition, Writing - review & editing,2,7 and Michael R. Wilson, Conceptualization, Formal analysis, Funding acquisition, Writing - original draft, Writing - review & editing3 Sandra C. Buttigieg, Editor

Publish date

2020

PMID

26870552

Abstract

The title compound, C21H21NO5, crystallizes with two mol­ecules in the asymmetric unit. In each mol­ecule, the central 1,4-di­hydro­pyridine ring adopts a shallow sofa conformations (with the C atom bearing the phenol ring as the flap), whereas the pendant cyclo­hexene rings both have twisted-boat conformations. Each mol­ecule features an intra­molecular O—H⋯O hydrogen bond, which closes an S(8) ring. In the crystal, the mol­ecules are linked by O—H⋯O, C—H⋯O and C—H⋯π inter­actions, forming a three-dimensional network.

KEYWORDS

crystal structure, acridines, acetic acid, hydrogen bonding, C—H⋯π inter­actions

Title

Crystal structure of 2-[9-(2-hy­droxy­phen­yl)-1,8-dioxo-1,2,3,4,5,6,7,8,9,10-deca­hydro­acridin-10-yl]acetic acid

Author

Mehmet Akkurt,a Jerry P. Jasinski,b Shaaban K. Mohamed,c,d Omyma A. Abd Allah,e Asmaa H. A. Tamam,e and Mustafa R. Albayatif,*

Publish date

2015 Dec 1;